Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that blocking the internal pathways that create androgens might help treat cancers that depend on sex hormones.

Myotonic dystrophy may be classified as a segmental progeroid disorder.

The UD-PrOZA program successfully diagnosed 18% of adult patients with rare diseases, often using genetic testing.

The article concludes that treating hair loss requires careful research, understanding the causes, and personalized treatment plans.

A significant number of Nigerian women struggling with infertility have Polycystic Ovary Syndrome, with the exact percentage varying based on the diagnostic criteria used.

Dermatologists are crucial in providing personalized care for patients with sex development differences.

Six genetic conditions are often linked to complete scalp hair loss in children.

New treatments are needed for PCOS that target its genetic, hormonal, and metabolic causes.

Genetic changes in mice help understand skin and hair disorders, aiding treatment development for acne and hair loss.

Autism's genetics are linked with early age of puberty and less hair loss, but not with hormone levels or polycystic ovary syndrome.

Congenital Adrenal Hyperplasia is a rare inherited disease causing hormone imbalances, affecting growth, fertility, and heart health, diagnosed through blood tests and treated with medication and lifestyle changes.

A woman with acne and baldness was found to have a rare ovarian condition but successfully had a child through fertility treatment.

A 23-year-old woman's missed periods were caused by a rare genetic disorder treated with hormone patches.

Ovarian hyperthecosis should be considered in young women with severe male-like symptoms and can be managed with hormone treatments.

GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.

Men with isolated hypogonadotropic hypogonadism have partial steroid deficiencies, while those with panhypopituitarism have severe deficiencies.

Male hypogonadism affects skin and hair, causing thin skin, less hair, and skin reactions to treatment.

Recombinant gonadotropins improve future fertility in CHH patients.

A new genetic mutation causes severe Leydig cell hypoplasia, affecting sexual development.

Removing both ovaries can treat increased testosterone and related symptoms in postmenopausal women with ovarian hyperthecosis.

New and future treatments for male hypogonadism include various forms of testosterone therapy and emerging drugs.

Testosterone replacement therapy should be used for men with low testosterone levels and symptoms of hypogonadism, after careful diagnosis and considering individual needs.

Ovarian stromal hyperplasia can cause high testosterone in postmenopausal women and is treated by removing the ovaries.

Chemotherapy for male germ cell tumors often leads to hypogonadism and related symptoms.

Using GnRHa agonists helps diagnose and treat ovarian hyperthecosis when surgery isn't possible.

New treatments for male hypogonadism are easier to use and target specific tissues to reduce side effects.

A postmenopausal woman's excess male hormone symptoms improved after her ovaries were removed.

The treatment successfully lowered testosterone levels and reduced symptoms.

Removing both ovaries may better treat increased male hormone levels and related symptoms in postmenopausal women when hormone therapy doesn't work.

Gonadal biopsy is the best method to diagnose gonadal dysgenesis.